Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
10.50
+1.34 (14.63%)
Aug 12, 2022 1:36 PM EDT - Market open
Balance Sheet (Trailing)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Quarter Ending | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents
|
143.64 | 351.41 | 368.76 | 358.79 | 169.6 | 42.86 | - | - | - | 9.25 |
Short-Term Investments
|
178.86 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 |
Cash & Cash Equivalents
|
322.5 | 351.41 | 368.76 | 358.79 | 169.6 | 42.86 | 0 | 0 | 0 | 9.25 |
Cash Growth
|
90.15% | 719.84% | - | - | - | 363.63% | - | - | - | - |
Other Current Assets
|
- | - | 1.76 | - | 2.11 | 0.73 | - | - | - | 0.51 |
Total Current Assets
|
320.37 | 348.67 | 370.52 | 358.29 | 171.71 | 43.59 | - | - | - | 9.76 |
Property, Plant & Equipment
|
20.31 | 12.33 | 11.8 | 8.92 | 7.73 | 4.62 | - | - | - | 1.34 |
Other Long-Term Assets
|
5.33 | 5.34 | 1.73 | 1.73 | 1.16 | 1.16 | - | - | - | 0 |
Total Long-Term Assets
|
25.64 | 17.66 | 13.53 | 10.65 | 8.9 | 5.79 | - | - | - | 1.34 |
Total Assets
|
346.01 | 366.33 | 384.05 | 368.94 | 180.6 | 49.38 | - | - | - | 11.09 |
Accounts Payable
|
4.51 | 6.56 | 3.53 | 7.46 | 7.33 | 7.07 | - | - | - | 3.2 |
Current Debt
|
1.52 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0.75 |
Other Current Liabilities
|
6.46 | 10.08 | 9.21 | 3.33 | 1.77 | 22.21 | - | - | - | 0.35 |
Total Current Liabilities
|
12.49 | 16.64 | 12.74 | 10.79 | 9.09 | 29.28 | - | - | - | 4.29 |
Long-Term Debt
|
5.46 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 |
Other Long-Term Liabilities
|
2.18 | 2.18 | 2 | 1.47 | 0.96 | 1.07 | - | - | - | - |
Total Long-Term Liabilities
|
7.64 | 2.18 | 2 | 1.47 | 0.96 | 1.07 | - | - | - | 0 |
Total Liabilities
|
20.13 | 18.81 | 14.74 | 12.26 | 10.05 | 30.34 | - | - | - | 4.29 |
Total Debt
|
6.98 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0.75 |
Common Stock
|
473.98 | 471.57 | 469.85 | 436.85 | 0.66 | 0.41 | 0 | 0 | 0 | 0.05 |
Retained Earnings
|
-145.97 | -122.04 | -98.6 | -78.76 | -60.35 | -48.08 | - | - | - | -12.2 |
Comprehensive Income
|
-2.13 | -2.02 | -1.95 | -1.42 | -0.92 | -1.06 | - | - | - | 0 |
Shareholders' Equity
|
325.88 | 347.52 | 369.31 | 356.68 | -60.62 | -48.73 | - | - | - | -12.15 |
Total Liabilities and Equity
|
346.01 | 366.33 | 384.05 | 368.94 | -50.57 | -18.39 | 0 | 0 | 0 | -7.86 |
Net Cash / Debt
|
315.52 | 351.41 | 368.76 | 358.79 | 169.6 | 42.86 | 0 | 0 | 0 | 8.5 |
Net Cash / Debt Growth
|
86.03% | 719.84% | - | - | - | 404.57% | - | - | - | - |
Net Cash Per Share
|
6.77 | 14.06 | 8.02 | 70.76 | 99.23 | 28.26 | - | - | - | 1.70 |
Working Capital
|
307.88 | 332.03 | 357.78 | 347.5 | 162.62 | 14.32 | - | - | - | 5.47 |
Book Value Per Share
|
6.99 | 13.90 | 8.03 | 70.34 | -35.46 | -32.12 | - | - | - | -2.43 |
Source: Financials are provided by
Nasdaq Data Link
and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).